People · Operator
Named in public records as an officer, director or promoter · active 2010–2024 · Biotechnology, Pharmaceuticals, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| eGenesis, Inc. | — | Biotechnology | Series D+ | $265.0M | $316.4M | 2019 |
| Lycera Corp | — | Pharmaceuticals | Series B | $85.7M | $1.0B | 2015 |
| Patientsafe Solutions, Inc. | — | Other Health Care | Series B | $76.7M | $332.3M | 2012 |
| BiomX Inc. | — | Pharmaceuticals | Series C | $72.3M | $16.9M | 2021 |
| Compugen Ltd | — | Biotechnology | Series B | $32.0M | $442.4M | 2018 |
| Macrogenics Inc | — | Biotechnology | Series A | $12.0M | $434.4M | 2011 |
| ARYx Therapeutics, Inc. | — | Pharmaceuticals | Seed | $2.4M | $76.6M | 2010 |
PAUL SEKHRI at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside PAUL SEKHRI on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 2 | 23 |
| Michael Steinmetz | 2 | 4 |
| John Kim | 1 | 23 |
| Kristina Burow | 1 | 16 |
| Jonathan Leff | 1 | 11 |
| Nina Kjellson | 1 | 11 |
| Arnold Oronsky | 1 | 10 |
| Ed Hurwitz | 1 | 9 |
| Lucio Iannone | 1 | 6 |
| Brad Smith | 1 | 6 |
| Bob More | 1 | 6 |
| Geoff MacKay | 1 | 5 |
| Isaac Ciechanover | 1 | 5 |
| LISA SUENNEN | 1 | 5 |
| Julie Sunderland | 1 | 5 |
| Kathleen M. Metters | 1 | 4 |
| Tim Mayleben | 1 | 4 |
| Timothy M. Mayleben | 1 | 4 |
| Joel Krikston | 1 | 4 |
| Paul Goddard | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.